Pay in 4 interest-free payments of $6.48 Learn more
Ships within 48 hours · Estimated delivery Sep 14 - Sep 19
Clamp AR, Schffski P, Valle JW, Wilson RH, Marreaud S, Govaerts AS et al (2008) A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer
For injury healing (muscles, tendons, ligaments) Standard protocol: Dose: 250-500mcg twice daily (500mcg-1mg total daily) Method: Injectable SubQ near injury site Duration: 4-8 weeks minimum Timing: Morning and evening Severe injuries: Dose: 500mcg twice daily (1mg total daily) Method: Injectable SubQ Duration: 8-12 weeks Can extend if needed Mild injuries: Dose: 250mcg twice daily (500mcg total) Method: Injectable SubQ Duration: 4-6 weeks Use our BPC-157 dosage calculator and BPC-157 5mg dosing guide
The cartilage/chondrocyte data supports this
showed immunization of mice against Gpnmb resulted in a reduction of Gpnmb-positive cells
Frequently Asked Questions What's the main difference between BPC-157 and GHK-Cu
Potential Side Effects and Safety Considerations General Tolerance GHK-Cu is considered safe and non-toxic , with a safety profile similar to placebo in clinical trials (Abdulghani et al., 1999)
US$ 25.93
US$ 25.81
US$ 22.01
US$ 29.46
US$ 24.34
US$ 24.48
